Emerging new evidence for the treatment of pulmonary sarcomatoid carcinoma

Emerging new evidence for the treatment of pulmonary sarcomatoid carcinoma

Tomohiro Akaba, Ken Arimura, Etsuko Tagaya

Department of Respiratory Medicine, Tokyo Women’s Medical University, Tokyo, Japan

Correspondence to: Tomohiro Akaba, MD, PhD. Department of Respiratory Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan. Email: akaba.tomohiro@twmu.ac.jp.

Comment on: Zhao C, Gao S, Xue Q, et al Clinical characteristics and prognostic factors of pulmonary sarcomatoid carcinoma. J Thorac Dis 2022; 14:3773-81.

Keywords: Treatment; prognostic factor; clinical characteristics; pulmonary sarcomatoid carcinoma (PSC)

Submitted Dec 11, 2022. Accepted for publication Feb 08, 2023. Published online Feb 23, 2023.

doi: 10.21037/jtd-22-1775

Lung cancer is a leading cause of cancer-related mortality, accounting for 1.8 million people worldwide in 2020 (1). Pulmonary sarcomatoid carcinoma (PSC) is a rare type of non-small cell lung cancer (NSCLC), characterized by poorly differentiated carcinoma with components of sarcoma or sarcoma-like differentiation. The most recent classification of PSC includes pleomorphic carcinoma, giant cell carcinoma, spindle cell carcinoma, pulmonary blastoma, and carcinosarcoma (2). Owing to the rapid advancement in cancer treatment and elucidation of disease mechanisms, the outcomes of lung cancer have drastically improved over the last decade. However, the prognosis of PSC is still poor compared to other forms of NSCLC (3,4). There is limited data regarding the standard treatment strategy, clinical characteristics, and prognostic factors due to the rarity of the disease. Therefore, this necessitates the accumulation of evidence for PSC.

In a recent study, Zhao et al. reported the long-term follow-up data of 119 patients with PSC in a single cancer center in China (5). The authors described the data regarding the main features of patients with PSC and disease prognosis, including median survival and 1-, 3-, and 5-year overall survival based on patient characteristics. In addition, they elucidated that the TNM stage, especially T staging and M staging, was associated with the prognosis of PSC. These data were consistent with previous studies (4,6,7).

Interestingly, more than 90% of patients underwent surgery in this study, and this proportion was substantially greater, despite the small number of stage IV patients. Since surgical resection is the only known curative treatment for PSC, the relatively good overall survival in this study may be partly attributed to a proactive surgical treatment strategy (6). As emphasized by the authors, complete resection of a tumor should be targeted based on the patient’s condition. However, mixed results exist on the effectiveness of chemotherapy in combination with surgery, and this study did not provide a definite conclusion regarding this point (4,6,8). Since a majority of the patients received adjuvant or neoadjuvant chemotherapy in current and previous studies, future studies focusing on the combination of chemotherapy and surgery are warranted (5,6).

To date, there is no standard treatment regimen for management of advanced-stage PSC. A previous study on a French cohort showed that platinum-based chemotherapy modestly improved the outcomes of patients with PSC (9). However, patients with PSC tend to develop chemotherapy resistance at an early stage, thereby resulting in less efficacy. Therefore, similar to other NSCLCs, other treatment strategies, such as molecular-targeted drugs and immune checkpoint inhibitors, may play an important role in the treatment of advanced-stage PSC. The current study showed that 8/18 (44%) patients with PSC were positive for mutations in genes such as KRAS, EGFR, and ALK. In addition, some PSC patients harbored the MET mutation, and MET and KRAS mutations were associated with poor prognosis (10,11). Although the effectiveness of molecular-targeted drugs for PSC has not been elucidated, a previous report showed that MET-TKI was effective in patients with MET exon 14 mutations (12). Patients with other driver gene mutations may also benefit from molecular-targeted treatment. Therefore, whole genome sequencing analysis might help in selection of an appropriate treatment regimen and improvement in the outcomes of PSC.

Similarly, since programmed death ligand-1 (PD-L1) expression tends to be high in PSC, patients with PSC may benefit from immunotherapy (13,14). A recent study confirmed that the patients treated with immune-checkpoint inhibitors as second-line treatment achieved a 40% response rate, which is significantly higher than conventional chemotherapy (15). Additionally, the combination of chemotherapy and immune checkpoint inhibitors was reported to be effective on a case-report basis (16,17).

In conclusion, multimodality treatment, including surgery, cytotoxic chemotherapy, tyrosine kinase inhibitors, and immune checkpoint inhibitors, is essential for effective management of PSC owing to its poor prognostic nature. The current study provided new insights into PSC; however, further prospective studies with a larger sample size are needed to fully elucidate the characteristics of PSC and the efficacy of emerging treatments such as molecular-targeted agents and immune checkpoint inhibitors.


Funding: None.


Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Thoracic Disease. The article did not undergo external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-1775/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.


  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. [Crossref] [PubMed]
  2. WHO Classification of Tumours Editorial Board. Thoracic Tumours (5th ed), International Agency for Research on Cancer, Lyon, France, 2021.
  3. Yendamuri S, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. Surgery 2012;152:397-402. [Crossref] [PubMed]
  4. Maneenil K, Xue Z, Liu M, et al. Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients. Clin Lung Cancer 2018;19:e323-33. [Crossref] [PubMed]
  5. Zhao C, Gao S, Xue Q, et al. Clinical characteristics and prognostic factors of pulmonary sarcomatoid carcinoma. J Thorac Dis 2022;14:3773-81. [Crossref] [PubMed]
  6. Park JS, Lee Y, Han J, et al. Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the lung. Oncology 2011;81:206-13. [Crossref] [PubMed]
  7. Sun J, Jiang Z, Shan T, et al. Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma. Front Oncol 2022;12:833486. [Crossref] [PubMed]
  8. Cen Y, Yang C, Ren J, et al. Additional chemotherapy improves survival in stage II-III pulmonary sarcomatoid carcinoma patients undergoing surgery: a propensity scoring matching analysis. Ann Transl Med 2021;9:24. [Crossref] [PubMed]
  9. Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol 2013;8:1574-7. [Crossref] [PubMed]
  10. Mignard X, Ruppert AM, Antoine M, et al. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. J Thorac Oncol 2018;13:1962-7. [Crossref] [PubMed]
  11. Lococo F, Gandolfi G, Rossi G, et al. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma. J Thorac Oncol 2016;11:1282-92. [Crossref] [PubMed]
  12. Gong C, Xiong H, Qin K, et al. MET alterations in advanced pulmonary sarcomatoid carcinoma. Front Oncol 2022;12:1017026. [Crossref] [PubMed]
  13. Vieira T, Antoine M, Hamard C, et al. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer 2016;98:51-8. [Crossref] [PubMed]
  14. Ma Y, Li W, Li Z, et al. Immunophenotyping of pulmonary sarcomatoid carcinoma. Front Immunol 2022;13:976739. [Crossref] [PubMed]
  15. Domblides C, Leroy K, Monnet I, et al. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. J Thorac Oncol 2020;15:860-6. [Crossref] [PubMed]
  16. Akaba T, Shiota Y, Onizawa F, et al. Recurrent spindle cell carcinoma of the lung successfully treated by chemoimmunotherapy. Respirol Case Rep 2021;9:e00757. [Crossref] [PubMed]
  17. Kawachi H, Kunimasa K, Kukita Y, et al. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. Immunotherapy 2021;13:799-806. [Crossref] [PubMed]
Cite this article as: Akaba T, Arimura K, Tagaya E. Emerging new evidence for the treatment of pulmonary sarcomatoid carcinoma. J Thorac Dis 2023;15(3):953-955. doi: 10.21037/jtd-22-1775

Download Citation